Global Gene Therapies for Cancer Treatment Competitive Landscape Professional Research Report 2024
Research Summary
Gene therapies for cancer treatment involve the introduction or modification of genetic material within a patient's cells to target and combat cancer. This innovative approach aims to address underlying genetic abnormalities responsible for the development and progression of cancer. Various strategies are employed, including introducing therapeutic genes, modifying existing genes, or utilizing gene editing technologies to enhance the body's ability to recognize and eliminate cancer cells. One prominent example involves using viral vectors to deliver therapeutic genes that instruct the immune system to recognize and attack cancer cells specifically. CAR-T cell therapy is a notable gene therapy for certain blood cancers, where a patient's T cells are engineered to express chimeric antigen receptors (CARs), allowing them to target and destroy cancer cells with precision. While gene therapies for cancer are still evolving, they represent a promising avenue for personalized and targeted treatment approaches, potentially revolutionizing cancer care by addressing the genetic basis of the disease. Ongoing research and clinical trials continue to explore and refine these therapeutic strategies.
According to DIResearch's in-depth investigation and research, the global Gene Therapies for Cancer Treatment market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.
The major global manufacturers of Gene Therapies for Cancer Treatment include Takara Bio, Tocagen, VBL Therapeutics, Cold Genesys, Genprex, Momotaro-Gene, MultiVir, SynerGene Therapeutics, Ziopharm Oncology, Anchiano Therapeutics, Celsion, Celgene, Bluebird Bio etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Gene Therapies for Cancer Treatment. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Gene Therapies for Cancer Treatment market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Gene Therapies for Cancer Treatment market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Gene Therapies for Cancer Treatment industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Gene Therapies for Cancer Treatment Include:
Takara Bio
Tocagen
VBL Therapeutics
Cold Genesys
Genprex
Momotaro-Gene
MultiVir
SynerGene Therapeutics
Ziopharm Oncology
Anchiano Therapeutics
Celsion
Celgene
Bluebird Bio
Gene Therapies for Cancer Treatment Product Segment Include:
Somatic Cell Gene Therapy (SCGT)
Germline Gene Therapy (GGT)
Gene Therapies for Cancer Treatment Product Application Include:
Cancer Research Centers
Diagnostic Laboratories
Cancer Hospitals
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Gene Therapies for Cancer Treatment Industry PESTEL Analysis
Chapter 3: Global Gene Therapies for Cancer Treatment Industry Porter’s Five Forces Analysis
Chapter 4: Global Gene Therapies for Cancer Treatment Major Regional Market Size and Forecast Analysis
Chapter 5: Global Gene Therapies for Cancer Treatment Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Gene Therapies for Cancer Treatment Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Gene Therapies for Cancer Treatment Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources